Navigation Links
Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters
Date:1/19/2009

Insightra Medical announced 510(k) clearance of their full range of 7Fr IAB catheters and immediate release in the United States.

Irvine, CA (PRWEB) January 19, 2009 -- Insightra Medical Inc., a privately held medical device company based in Irvine, California, markets the most complete range of 7Fr IAB catheters in sizes including: 40cc, 35cc, 30cc, 25cc and 20cc, all in a true 7Fr diameter.

"We want to offer customers product flexibility and a very high level of quality," says Brad Sharp, CEO of Insightra. "The market seems to agree that 7Fr is a big improvement in terms of distal flow, comfort and safety. The key is to deliver that 7Fr benefit to the entire population, and not just those who fit the most popular sizes. That is why we have brought such a complete offering to market."

The balloon catheter already has CE mark approval and is selling globally; the addition of FDA clearance allows Insightra to bring the benefits of this offering to the United States, the largest market for IAB catheters.

The patented 7Fr catheter design is the largest range of that size which utilizes a standard fluid filled core, a proven technology in IAB pumping. This key feature means the catheters can be used on virtually any older model of balloon pump, while being fully compatible with the latest balloon pumps on the market (1). By being broadly compatible, hospitals are not required to upgrade their older machines to newer fiber-optic consoles; a huge cost saving.

The balloon at the heart of the kit has been used in Japan for over 8 years on a wide variety of machines and has clinically demonstrated to perform as well as an 8Fr balloon, even with difficult tachycardia patients. The balloon, which was one of the first to be
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. NTU and Insightra Medical Inc. release their first joint venture medical device
2. China Sky One Medical, Inc. Provides Business Update
3. Thermage, Inc. Announces Name Change to Solta Medical, Inc.
4. China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs
5. "The Economic Report" Show to Feature Gradient Medical, LLC
6. China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs
7. China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO
8. CPC Launches New Web Site Highlighting Medical, Research and Technical Panel, MedClose(TM) VCS Animated Video
9. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
10. Vertos Medical, Inc. Appoints James M. Corbett Chief Executive Officer
11. Interview with Dr. Elisabeth Hager, CEO of Balan Biomedical, Inc., to Air Nationally on Sky Radio
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters 
Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters
Breaking Medicine Technology:Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 2Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 3Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 4Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 5Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 6Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 7Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 8Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 9GE Healthcare President 26 CEO Mark Vachon to Present at BioConference Live 10595 1GE Healthcare President 26 CEO Mark Vachon to Present at BioConference Live 10595 2Hepatitis B does not increase risk for pancreatic cancer 60451 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 3
Other Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8